Professor Ruth Langley
Professor Ruth Langley, based at University College London, is leading an international clinical trial called Add-Aspirin. The trial is looking at whether aspirin could help stop some types of cancer from coming back after treatment.
Over the last few years, evidence has emerged suggesting that aspirin could help prevent some cancers from returning. Although this is an exciting lead, much more research is still needed into aspirin’s benefits and risks, as it can have harmful side effects.
Trials like the Add-Aspirin trial will help researchers work out who is most likely to benefit from taking aspirin, and how best to use it in cancer medicine. Stopping cancer from coming back after treatment is an important challenge, and finding new ways to do so could help to boost long-term survival.
You can read more about the Add-Aspirin clinical trial in our press release.